Cargando…
Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy
Cryptococcus neoformans infections occur mostly in immunodeficient individuals, being the most common opportunistic fungal central nervous system (CNS) infection in HIV seropositive patients. Moreover, other conditions affecting host immunity, such as hematologic malignancies, organ transplantation...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512028/ https://www.ncbi.nlm.nih.gov/pubmed/33024550 http://dx.doi.org/10.12688/f1000research.24816.2 |
_version_ | 1783586073621823488 |
---|---|
author | Cunha Pereira, Tatiana Rb-Silva, Rita Félix Soares, Rita Domingues, Nelson Mariz, José |
author_facet | Cunha Pereira, Tatiana Rb-Silva, Rita Félix Soares, Rita Domingues, Nelson Mariz, José |
author_sort | Cunha Pereira, Tatiana |
collection | PubMed |
description | Cryptococcus neoformans infections occur mostly in immunodeficient individuals, being the most common opportunistic fungal central nervous system (CNS) infection in HIV seropositive patients. Moreover, other conditions affecting host immunity, such as hematologic malignancies, organ transplantation and immunosuppressive drugs are implicated as risk factors. The authors present a case of a 48-year-old male with Hodgkin Lymphoma for 26 years and submitted to several lines of treatment, diagnosed with cryptococcal meningitis while on therapy with brentuximab. The patient presented with positive cerebral spinal fluid (CSF) cryptococcal antigen plus positive blood cultures. He was put under induction antifungal treatment with liposomal amphotericin B and flucytosine, as well as corticosteroid therapy with dexamethasone with headache improvement and a favorable clinical evolution. There are no reported cases of cryptococcal meningoencephalitis under CD30-directed monoclonal antibody. Furthermore, this case illustrates the risk of Cryptococcus neoformans infection in immunocompromising conditions other than HIV, underlining the need of considering this differential diagnosis when physicians face an opportunistic neuroinfection. |
format | Online Article Text |
id | pubmed-7512028 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-75120282020-10-05 Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy Cunha Pereira, Tatiana Rb-Silva, Rita Félix Soares, Rita Domingues, Nelson Mariz, José F1000Res Case Report Cryptococcus neoformans infections occur mostly in immunodeficient individuals, being the most common opportunistic fungal central nervous system (CNS) infection in HIV seropositive patients. Moreover, other conditions affecting host immunity, such as hematologic malignancies, organ transplantation and immunosuppressive drugs are implicated as risk factors. The authors present a case of a 48-year-old male with Hodgkin Lymphoma for 26 years and submitted to several lines of treatment, diagnosed with cryptococcal meningitis while on therapy with brentuximab. The patient presented with positive cerebral spinal fluid (CSF) cryptococcal antigen plus positive blood cultures. He was put under induction antifungal treatment with liposomal amphotericin B and flucytosine, as well as corticosteroid therapy with dexamethasone with headache improvement and a favorable clinical evolution. There are no reported cases of cryptococcal meningoencephalitis under CD30-directed monoclonal antibody. Furthermore, this case illustrates the risk of Cryptococcus neoformans infection in immunocompromising conditions other than HIV, underlining the need of considering this differential diagnosis when physicians face an opportunistic neuroinfection. F1000 Research Limited 2020-08-12 /pmc/articles/PMC7512028/ /pubmed/33024550 http://dx.doi.org/10.12688/f1000research.24816.2 Text en Copyright: © 2020 Cunha Pereira T et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Cunha Pereira, Tatiana Rb-Silva, Rita Félix Soares, Rita Domingues, Nelson Mariz, José Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy |
title | Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy |
title_full | Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy |
title_fullStr | Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy |
title_full_unstemmed | Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy |
title_short | Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy |
title_sort | case report: cryptococcal meningitis in hodgkin’s lymphoma patient receiving brentuximab-vedotin therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7512028/ https://www.ncbi.nlm.nih.gov/pubmed/33024550 http://dx.doi.org/10.12688/f1000research.24816.2 |
work_keys_str_mv | AT cunhapereiratatiana casereportcryptococcalmeningitisinhodgkinslymphomapatientreceivingbrentuximabvedotintherapy AT rbsilvarita casereportcryptococcalmeningitisinhodgkinslymphomapatientreceivingbrentuximabvedotintherapy AT felixsoaresrita casereportcryptococcalmeningitisinhodgkinslymphomapatientreceivingbrentuximabvedotintherapy AT dominguesnelson casereportcryptococcalmeningitisinhodgkinslymphomapatientreceivingbrentuximabvedotintherapy AT marizjose casereportcryptococcalmeningitisinhodgkinslymphomapatientreceivingbrentuximabvedotintherapy |